Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide: present and future in multiple myeloma.

Mohamad A Hussein1

  • 1Cleveland Clinic Multidisciplinary Multiple Myeloma Research Program, Cleveland, OH 44195, USA. mah+er@runbox.us

Expert Review of Anticancer Therapy
|March 11, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials.

Blood cancer journal·2018
Same author

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.

Clinical cancer research : an official journal of the American Association for Cancer Research·2017
Same author

Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.

Leukemia & lymphoma·2015
Same author

A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.

Cancer medicine·2014
Same author

Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.

American journal of hematology·2013
Same author

Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma.

American journal of hematology·2013
Same journal

Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine.

Expert review of anticancer therapy·2026
Same journal

Barriers to the use of brachytherapy for treatment of cervical cancer and prostate cancer in low- and middle-income countries.

Expert review of anticancer therapy·2026
Same journal

The dual role of Schlafen11 in brain tumors: Jekyll and Hyde.

Expert review of anticancer therapy·2026
Same journal

Central nervous system-related permanent consequences in long-term survivors of pediatric Langerhans cell histiocytosis: a clinical overview and monitoring strategies.

Expert review of anticancer therapy·2026
Same journal

RTsDEN: reverse task attention enabled deep learning model for lung cancer detection using computed tomography.

Expert review of anticancer therapy·2026
Same journal

The potential impact of glucagon-like peptide 1 receptor agonists for the treatment of endometrial carcinoma.

Expert review of anticancer therapy·2026
See all related articles

Multiple myeloma remains incurable, but immunomodulatory drugs like thalidomide offer effective treatment options. Research into thalidomide

Area of Science:

  • Hematology
  • Immunology
  • Pharmacology

Background:

  • Multiple myeloma is a currently incurable plasma cell malignancy.
  • Advances in understanding disease pathophysiology have been driven by immunomodulatory agents.
  • Thalidomide pioneered immunomodulatory therapy for multiple myeloma.

Purpose of the Study:

  • To review the role and mechanism of action of thalidomide in multiple myeloma.
  • To highlight thalidomide's efficacy in various stages of multiple myeloma.
  • To discuss the side-effect profile and management of thalidomide.

Main Methods:

  • Review of in vitro and in vivo studies on thalidomide.
  • Analysis of clinical data regarding thalidomide's efficacy and safety.
  • Exploration of the mechanism of action of immunomodulatory drugs.

Related Experiment Videos

Main Results:

  • Thalidomide demonstrated significant efficacy in treating multiple myeloma.
  • The drug maintains response rates in both newly diagnosed and relapsed/refractory patients.
  • Understanding thalidomide's mechanism advanced the study of plasma cell dyscrasias.

Conclusions:

  • Thalidomide is a unique and effective therapeutic agent for multiple myeloma.
  • Appropriate management of its side effects is crucial for optimal use.
  • Continued research into immunomodulatory agents is vital for advancing multiple myeloma treatment.